BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• BioMarin has a consensus “Moderate Buy” rating from 26 analysts: 16 recommend buying, three strongly recommend buying, six rate it a hold, and one recommends selling. The average 12-month price target is $88.60.
• Institutional investors own 98.71% of the company, with several investment firms increasing their stakes or initiating new positions during the third quarter.
• In its latest quarter, BioMarin reported EPS of $1.20 versus the $0.95 consensus and revenue of $989.71 million, up 20% year over year and above analyst expectations.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, sixteen have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $88.60.

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group increased their target price on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a "buy" rating in a research note on Monday, August 31st. Canaccord Genuity Group raised their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Citigroup lifted their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research note on Thursday, July 16th. Cantor Fitzgerald reiterated an "overweight" rating and set a $86.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, October 20th. Finally, Piper Sandler increased their price objective on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 1st.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Signaturefd LLC boosted its holdings in BioMarin Pharmaceutical by 16.7% during the 3rd quarter. Signaturefd LLC now owns 2,316 shares of the biotechnology company's stock valued at $139,000 after acquiring an additional 331 shares during the period. Root Financial Partners LLC bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at $88,000. Quadrant Capital Group LLC purchased a new stake in BioMarin Pharmaceutical in the third quarter worth $564,000. Nisa Investment Advisors LLC increased its stake in BioMarin Pharmaceutical by 13.3% in the third quarter. Nisa Investment Advisors LLC now owns 4,659 shares of the biotechnology company's stock worth $280,000 after purchasing an additional 546 shares during the period. Finally, Secure Asset Management LLC increased its stake in BioMarin Pharmaceutical by 3.0% in the third quarter. Secure Asset Management LLC now owns 80,592 shares of the biotechnology company's stock worth $4,835,000 after purchasing an additional 2,384 shares during the period. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $55.95 on Monday. The stock has a market cap of $10.83 billion, a price-to-earnings ratio of 151.22, a price-to-earnings-growth ratio of 0.61 and a beta of 0.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The stock has a 50 day moving average price of $61.70 and a 200-day moving average price of $58.67. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.25. The company had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. BioMarin Pharmaceutical's quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts expect that BioMarin Pharmaceutical will post 2.59 EPS for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company's research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin's marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.